Funding for this research was provided by:
Bill and Melinda Gates Foundation (RR374-092/S000690, RR374-053/4893196)
Received: 13 November 2017
Accepted: 8 January 2018
First Online: 29 January 2018
Ethics approval and consent to participate
: This study protocol has been approved by the institutional research commissions of CSRS in Abidjan and Swiss TPH in Basel. Ethical approval was obtained from the ethics committees in Switzerland: “Ethikkommission Nordwest- und Zentralschweiz (EKNZ)” (reference no. UBE-15/34; date of approval 15 April 2015) and in Côte d’Ivoire: Comité National d’Éthique et de la Recherche, Ministère de la Santé et de Lutte contre le SIDA (reference no. 007/MSLS/CNER-kp; date of approval 2 February 2016) and Direction Générale des Productions et de la Sécurité Alimentaire, Ministère de l’Agriculture, (reference no. 0163/MINAGRI/DGPSA/DPVCQ; date of approval 27 January 2015). Written informed consent will be sought from adults and parents or legal guardians of children below the age of 18 years. Children aged between 5 and 18 years will sign an informed assent form. Participation is voluntary and study participants have the right to withdraw from the study at any given point in time with no further obligations. Subjects will be treated free of charge once or twice a year with praziquantel and with albendazole.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.